In summary, this retrospective study of 1314 melanoma samples contributes to existing data that TMB, PD-L1, and other traditional biomarkers are poor predictors of immunogenicity in MBM, which instead may engage multiple intersecting pathways for immune evasion, including cytokine signaling, angiogenesis, and OXPHOS metabolism. The gene discussed is CD274; the disease is melanoma.